RAPID LOW-COST DETECTION OF TYPE 2CALR MUTATION BY ALLELE-SPECIFIC RT-PCR FOR DIAGNOSIS OF MYELOPROLIFERATIVE NEOPLASMS

Authors

  • M.V. Dybkov Institute of Molecular Biology and Genetics
  • M.P. Zavelevich R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • D.F. Gluzman R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • G.D. Telegeev Institute of Molecular Biology and Genetics

DOI:

https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-1.17329

Keywords:

allele-specific PCR, calreticulin, essential thrombocythemia, mutation., myeloproliferative neoplasms

Abstract

Background: Approximately 15% to 24% of essential thrombocythemia (ET) and 25–35% of primary myelofibrosis cases carry a mutation in the calreticulin (CALR) gene. Sanger sequencing, qPCR, high resolution melt or targeted next generation sequencing usually used to detect these mutations are expensive and require costly equipment. Nevertheless, type 1 CALR mutations are detectable by using polymerase chain reaction (PCR) and agarose gel electrophoresis. Aim: To offer the use of the allele-specific reverse transcription (RT) PCR for rapid low-cost detection of the type 2 mutation in the CALR gene. Materials and Methods: Allele-specific primers designed for detecting type 2 mutation (5-bp insertion; c.1154_1155 ins TTGTC) of the CALR gene were used for allele-specific RT-PCR analysis of cDNA of the patient with JAK2-, MPL-negative ET, whose mutation in CALR gene has been identified by Sanger sequencing. RT-PCR samples were analyzed by agarose gel electrophoresis. Results: The type 2 mutation (K385fs*47 ins5) in CALR gene was detected by Sanger sequencing in JAK2- and MPL-negative ET patient. The cDNA obtained was then re-analyzed by using allele-specific RT-PCR with newly designed primers. Normal and type 2 mutation alleles of the CALR gene were detected by gel electrophoresis. The results of allele-specific RT-PCR were consistent with the data of Sanger sequencing. Conclusion: Allele-specific RT-PCR analysis may be used for the fast low-cost detection of the major type 2 mutation (ins 5) of the CALR gene in patients with MPNs.

References

Verstovsek S, Tefferi A. Myeloproliferative Neoplasms: Biology and Therapy (Contemporary Hematology). Humana Press, 2011. 230 p. ISBN: 978-1-60761-266-7

Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue (IARC WHO Classification of Tumours), Fourth Edition. Lyon: IARC Press, 2008. 439 p. ISBN-13 9789283244943

Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391–405. https://doi.org/10.1182/blood-2016-03-643544

Finazzi G, Harrison C. Essential thrombocythemia. Semin Hematol 2005; 42: 230–8. https://doi.org/10.1053/j.seminhematol.2005.05.022

Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–61. https://doi.org/10.1016/s0140-6736(05)71142-9

Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–97. https://doi.org/10.1016/j.ccr.2005.03.023

Pardanani A, Levine R, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108: 3472–6. https://doi.org/10.1182/blood-2006-04-018879

Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379–90. https://doi.org/10.1056/nejmoa1311347

Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369: 2391–405. https://doi.org/10.1056/nejmoa1312542

Tefferi A, Barbui B. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. Am J Hematol 2019; 94: 133–43. https://doi.org/10.1002/ajh.25303

Jones AV, Ward D, Lyon M, et al. Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms. Leukemia 2015; 39: 82–7. https://doi.org/10.1016/j.leukres.2014.11.019

Cabagnols X, Defour JP, Ugo V, et al. Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution. Leukemia 2015; 29: 249–52. https://doi.org/10.1038/leu.2014.270

Zinke M, Nageswaran V, Reinhardt R, et al. Rapid and sensitive detection of calreticulin type 1 and 2 mutations by real-time quantitative PCR Mol Diagn Ther 2015; 19: 329–34. https://doi.org/10.1007/s40291-015-0162-3

Dybkov MV, Gartovska IR, Maliuta SS, et al. Detection of V617F mutation of gene jak2 at patients with chronic myeloproliferative neoplasms. Biopolym Cell 2010; 26: 214–7. http://dx.doi.org/10.7124/bc.000159

Gluzman DF, Sklyarenko LM, Zavelevich MP, et al. Complex diagnosis of myeloid neoplasms in regional oncological centers. Science and Innovation (Nauka Innov) 2013; 9: 61–72. http://dx.doi.org/10.15407/scin9.06.061

Gluzman DF, Sklyarenko LM, Telegeev GD, et al. Dia¬gnostics of acute leukemia and myeloproliferative neoplasms Scientific-practical guide. Kyiv: DIA, 2016. 124 p (in Russian). ISBN 978-617-7015-40-5

Downloads

Published

26.05.2023

How to Cite

Dybkov, M., Zavelevich, M., Gluzman, D., & Telegeev, G. (2023). RAPID LOW-COST DETECTION OF TYPE 2CALR MUTATION BY ALLELE-SPECIFIC RT-PCR FOR DIAGNOSIS OF MYELOPROLIFERATIVE NEOPLASMS. Experimental Oncology, 44(1), 83–86. https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-1.17329

Issue

Section

Methods and techniques